Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroGen’s 10-K isn’t just long—it’s layered with clinical data, collaboration accounting, and patent tables that can overwhelm even seasoned analysts. Pinpointing when a Phase 3 trial might impact revenue or why deferred payments surged requires hours of line-by-line reading.
Stock Titan turns that challenge into a three-minute scan. Our AI produces clear, section-by-section summaries, so understanding FibroGen SEC documents with AI feels straightforward. Want the highlight reel from the latest FibroGen quarterly earnings report 10-Q filing? We flag new trial costs and cash-runway updates. Need FibroGen Form 4 insider transactions real-time? Instant alerts show executive buys and sells, giving context around data-release dates. Every filing—10-K, 10-Q, 8-K, S-8, or DEF 14A—is posted within minutes of hitting EDGAR and paired with concise commentary.
Here’s how professionals use the page:
- Track FibroGen insider trading Form 4 transactions before pivotal readouts.
- Compare R&D spend trends with our FibroGen earnings report filing analysis.
- See partnership milestone revenue explained inside an FibroGen 8-K material events explained digest.
- Review pay packages via the FibroGen proxy statement executive compensation breakdown.
- Dive into pipeline risk factors with the FibroGen annual report 10-K simplified summary.
- Monitor FibroGen executive stock transactions Form 4 to gauge insider sentiment.
Whether you’re a buy-side analyst modeling cash burn or a physician-investor following antibody-drug conjugate progress, our platform delivers the insight you need—without wading through 200-page PDFs. FibroGen SEC filings explained simply starts here.
David DeLucia, Chief Financial Officer of FibroGen, Inc. (FGEN), reported two dispositions of common stock that were withheld to satisfy tax obligations arising from the vesting of restricted stock units. The Form 4 lists a transaction on 06/06/2025 showing a disposition at a price of $7.8325 and a reported beneficial ownership of 4,594 shares following the transaction. A second reported disposition on 09/06/2025 shows a price of $12.10 and a reported beneficial ownership of 4,541 shares following that transaction. The filer states these shares were withheld by the issuer to cover taxes on RSU vesting. The filing notes a 1-for-25 reverse stock split effective June 16, 2025. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Thane Wettig, listed as CEO and Director of FibroGen, Inc. (FGEN), reported two stock disposals in 2025 and an indirect holding by his spouse. On 06/06/2025 he disposed of 21,487 shares at a reported price of $7.8325, and on 09/06/2025 he disposed of 21,239 shares at $12.10. The filing states these share amounts were withheld by the issuer to satisfy a tax obligation arising from the vesting of restricted stock units.
The form also notes an indirect beneficial ownership of 40 shares by his spouse. A 1-for-25 reverse stock split effective June 16, 2025 is disclosed and the reported share counts and prices reflect that split. The form is signed by an attorney-in-fact on behalf of the reporting person.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.
FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.
FAQ
What is the current stock price of Fibrogen (FGEN)?
What is the market cap of Fibrogen (FGEN)?
